Search

Food colors are pervasive in our diet. However, some of them are involved in health concerns reaching carcinogenicity and reproductive toxicity. This is a survey of prepackaged color additives marketed to the simple consumer in Algeria. This exploration aimed to assess the compliance of the labeling of color additives, as well as the investigation of the presence of harmful dyes, namely E102, E110, E 121, E122, E123, E124, E127, E129, E132, E133, E143, and E171, in their composition. Our findings reveal the labeling compliance of 50.5% of analyzed coloring products and the absence of ingredient labeling for 1.6% of analyzed coloring products. While 47.8% of the products displayed different labeling flaws. Except for the dyes E121, E129, and E143, the other requested dyes have been determined. In fact, dyes E102 (39%), E110 (23%), and E171 (20%) were the most frequent. Moreover, 32.6% of all analyzed coloring products included two harmful dyes. Surprisingly, almost 3% of all assessed coloring products provided three harmful dyes simultaneously. Taken together, these results encourage further investigations of the presence of harmful dyes in our food and to establish more stringent rules governing the marketing and the use of coloring additives.

Due to the emergence of various highly contagious variants of SARS-CoV-2, vaccine boosters were adopted as a complementary strategy in different countries. This strategy has, however, posed another challenge for the national authorities to convince their population to receive the booster after the first challenge of COVID-19 primer dose vaccines. This study was conducted to determine COVID-19 vaccine booster acceptance and its associated factors in the general population in Algeria. Using social media platforms, an online self-administered questionnaire was distributed between 28 January and 5 March 2022 for all Algerian citizens who received COVID-19 vaccines. Overall, 787 respondents were included in this study. Among them, 51.6%, 25%, and 23.8% accepted, rejected, or were hesitant about the COVID-19 vaccine booster, respectively. However, only 13.2% declared receiving the booster dose. Additionally, while 58.2% of the respondents declared being relieved after primer vaccination, 11.4% among them declared that they regretted being vaccinated. The most common reasons for acceptance were experts’ recommendations (24.6%) and the belief that COVID-19 vaccine boosters were necessary and efficient, while rejection was mainly due to the belief that primer doses are sufficient (15.5%), or that vaccination in general is inefficient (8%). Males, older individuals, those with chronic comorbidities or a history of COVID-19 infection, non-healthcare workers, and those with low educational levels were associated with significantly higher odds for booster acceptance. Moreover, belief that booster doses were necessary and efficient, disagreeing with the notion that primer doses were not sufficient, experts’ recommendations, and the desire to travel abroad were significantly associated with higher odds of COVID-19 vaccine booster acceptance.

Hesitancy towards COVID-19 vaccination and its rejection remains a major public health concern worldwide, especially in the Middle East and North African countries. The current study aimed to assess the intentions to get COVID-19 vaccines and its determinants among the general public in Algeria.A self-administered online survey was distributed during August-September 2021 using a convenience-based sampling approach. Data were collected anonymously and analyzed using IBM SPSS v22.0 software.The study sample comprised a total of 656 participants, with 51.1% being in favor of COVID-19 vaccines while 18.5% and 30.5% were against or hesitant respectively. Only 38.6% among the study participants got vaccinated. Factors associated with higher odds of acceptance were: male sex, healthcare profession, the belief in natural origin of the pandemic and previous COVID-19 infection in family. The most common cited reasons for COVID-19 vaccine acceptance were the belief that vaccination is the only way to fight COVID-19 and the fear of getting infected by the virus; while the most common reasons of rejection were lack of trust in proper vaccine testing and fear of side effects.The overall level of COVID-19 vaccine acceptance in this study was below the levels required to achieve population immunity. Besides certain socio-demographic characteristics, the determinants of COVID-19 vaccine rejection included the embrace of conspiratorial ideas regarding the virus and its vaccination. This should be considered in implementation of interventional measures aiming to promote COVID-19 vaccination in the country.Las dudas sobre la vacuna contra la COVID-19 y el rechazo a la misma siguen siendo un gran problema de salud pública a nivel mundial, especialmente en Oriente Medio y los países del norte de África. El objetivo del estudio actual es evaluar la intención de recibir las vacunas contra la COVID-19 y sus determinantes entre el público general de Argelia.Se distribuyó una encuesta autoadministrada durante agosto-septiembre de 2021, utilizando un enfoque de muestreo basado en conveniencia. Los datos fueron recopilados de manera anónima utilizando el software IBM SPSS v22.0.La muestra del estudio incluyó un total de 656 participantes, de los cuales el 51,1% estuvo a favor de las vacunas contra la COVID-19, y el 18,5% y el 30,5% estuvo en contra o tuvo dudas, respectivamente. Solo el 38,6% de los participantes del estudio acudió a vacunarse. Los factores asociados a las mayores probabilidades de aceptación fueron: sexo masculino, profesión sanitaria, creencia en el origen natural de la pandemia e infección por COVID-19 previa en la familia. Los motivos más comúnmente citados para la aceptación de la vacuna contra la COVID-19 fueron la creencia en que la vacuna es el único modo de luchar contra la enfermedad, y el miedo a infectarse por el virus, mientras que los motivos más comunes de rechazo fueron la falta de confianza en las pruebas de la propia vacuna y el miedo a los efectos secundarios.El nivel general de aceptación de la vacuna contra la COVID-19 en este estudio estuvo por debajo de los niveles requeridos para lograr la inmunidad de la población. Además de ciertas características socio-demográficas, los determinantes del rechazo a la vacuna contra la COVID-19 incluyeron la adhesión a ideas conspiratorias en cuanto al virus y su vacuna. Esto deberá considerarse a la hora de implementar medidas intervencionistas encaminadas a promover la vacuna contra la COVID-19 en el país.

COVID-19 booster vaccines have been adopted in almost all countries to enhance the immune response and combat the emergence of new variants. Algeria adopted this strategy in November 2021. This study was conducted to consider the self-reported side effects of COVID-19 booster vaccines by Algerians who were vaccinated with a booster dose of one of the approved inactivated-virus vaccines, such as BBIBP-CorV and CoronaVac, or one of the adenoviral-vector-based vaccines, such as Gam-COVID-Vac, AZD1222 and Ad26.COV2.S, and to determine the eventual risk factors. A cross-sectional study using an online self-administered questionnaire (SAQ) was conducted in Algeria between 28 April 2022, and 20 July 2022. A descriptive analysis of the 196 individuals who were included showed a nearly equal distribution of adenoviral- (52%) and inactivated-virus vaccines (48%) and of males (49.5%) and females (50.5%). The results showed that 74.7% of the studied population reported at least one local or systemic side effect. These side effects were more frequent among adenoviral-vector vaccinees (87.3%) than inactivated-virus vaccinees (60.6%) (sig. < 0.001). Injection site pain (40.3%), heat at the injection site (21.4%), and arm pain (16.3%) were the most common local side effects. These signs generally appeared in the first 12 h (73.3%) and generally lasted less than 24 h (32.8%). More interestingly, these signs differed from those that followed the administration of primer doses (48.5%) and were generally more severe (37%). The same observation was reported for systemic side effects, where the signs were especially most severe in the adenoviral-vaccinated group (49.4% vs. 20.8%; sig. = 0.001). These signs generally appeared within the first day (63.6%) and mostly disappeared before two days (50.8%), with fatigue (41.8%), fever (41.3%), and headache (30.1%) being the most common. Adenoviral-vector vaccinees (62.7%) were more likely to use medications to manage these side effects than were inactivated-virus vaccinees (45.7%) (sig. = 0.035) and paracetamol (48.5%) was the most used medication. Adenoviral-based vaccines were the types of vaccines that were most likely to cause side effects. In addition, being female increased the risk of developing side effects; regular medication was associated with local side effects among inactivated-virus vaccinees; and previous infection with COVID-19 was associated with systemic and local side effects among adenovirus-based vaccinees. These results support the short-term safety of booster vaccines, as has been reported for primer doses.

Marek's disease virus (MDV) is a highly contagious alphaherpesvirus that infects chickens and causes a deadly neoplastic disease. We previously demonstrated that MDV infection arrests cells in S phase and that the tegument protein VP22 plays a major role in this process. In addition, expression of VP22 induces double-strand breaks (DSBs) in the cellular DNA, suggesting that DNA damage and the associated cellular response might be favorable for the MDV life cycle. Here, we addressed the role of DNA damage in MDV replication and pathogenesis. We demonstrated that MDV induces DSBs during lytic infection in vitro and in the peripheral blood mononuclear cells of infected animals. Intriguingly, we did not observe DNA damage in latently infected MDV-induced lymphoblastoid cells, while MDV reactivation resulted in the onset of DNA lesions, suggesting that DNA damage and/or the resulting DNA damage response might be required for efficient MDV replication and reactivation. In addition, reactivation was significantly enhanced by the induction of DNA damage using a number of chemicals. Finally, we used recombinant viruses to show that VP22 is required for the induction of DNA damage in vivo and that this likely contributes to viral oncogenesis. IMPORTANCE Marek's disease virus is an oncogenic alphaherpesvirus that causes fatal T-cell lymphomas in chickens. MDV causes substantial losses in the poultry industry and is also used in small-animal models for virus-induced tumor formation. DNA damage not only is implicated in tumor development but also aids in the life cycle of several viruses; however, its role in MDV replication, latency, and reactivation remains elusive. Here, we demonstrate that MDV induces DNA lesions during lytic replication in vitro and in vivo . DNA damage was not observed in latently infected cells; however, it was reinitiated during reactivation. Reactivation was significantly enhanced by the induction of DNA damage. Recombinant viruses that lacked the ability to induce DNA damage were defective in their ability to induce tumors, suggesting that DNA damage might also contribute to cellular transformation processes leading to MDV lymphomagenesis.